Abstract
Myelodysplastic syndrome (MDS) is clonal disease of hemopoietic tissue. It includes heterogeneous group of diseases with characteristics discrepancy between cellular bone marrow and peripheral pancytopenia and risk od transformation to acute leukemia.
Using to FAB classification MDS id divided into 5 subgroups and according to recently developed WHO classification into 8 groups. The whole entity is divided into low and high risk MDS using IPSS (International prognostic scoring system) and newly WPSS (WHO-based prognostic scoring system).